1. Home > Latest Topics >

Question 12: Pharmacokinetic/pharmacodynamic variables for respiratory fluoroquinolones against Streptococcus pneumoniae

20 June, 2018

question_12_9


LATEST TOPICS

Navigating antibiotic resistance in community-acquired pneumonia: Insights from Vietnam
29 October, 2024
Optimising antibiotic therapy: Insights on transitioning from intravenous to oral treatment for community-acquired pneumonia
27 September, 2024
Community-acquired pneumonia in Cambodia: Navigating the growing challenge of AMR
30 June, 2024
Managing Infectious Diseases in Emergency Medicine: A Specialist’s Approach
10 April, 2024
Advancing standardised diagnosis and treatment of acute infectious disease: Insights from an expert in theory–technique integration
08 April, 2024

RELATED ARTICLES

Antibiotic resistance may be driven by diverse factors, including extreme climatic events
14 February, 2024
Observing the Development of Quinolones from the Rational Application of Antibacterial Drugs During the COVID-19 Pandemic
21 March, 2023
Pharmacokinetic and microbial susceptibility studies of sitafloxacin
10 February, 2023
Advances in Diagnosing and Treating AECOPD
18 October, 2023
60-year development of quinolones (2): The clinical application of traditional classic quinolones and new quinolones
13 October, 2022